Developing Disruptive Therapeutics for the Treatment of  Patients with Urgent Unmet Medical Needs

Multi-Targeted Approach to Reset Dysregulated Biology: Polyamines are key regulators of normal biology and are altered in many disease states.  The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies.  Our Polyamine Metabolic Inhibitor (PMI) drug targeting strategies may allow for product opportunities in therapeutic areas of high unmet medical need, including oncology and orphan diseases.

Polyamine Metabolic Inhibitor (PMI)

Multi-Targeted Approach to Reset Dysregulated Biology: Polyamines are key regulators of normal biology and are altered in many disease states. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies. Our Polyamine Metabolic Inhibitor (PMI) drug targeting strategies may allow for product opportunities in therapeutic areas of high unmet medical need, including oncology and orphan diseases.

Clinical Trials

Panbela Therapeutics, Inc. is conducting trials from pre-clinical to Phase III registration programs. Late-stage programs are orphan oncology related: pancreatic cancer and FAP (familial adenomatous polyposis). In pancreatic cancer, the ASPIRE trial, a Global Randomized Double-Blind Placebo Controlled Trial of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma is open with a target of 60-80 sites. The FAP Phase III Registration trial is a partnered program anticipated to begin in the first half of 2023.